Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people who complete one month on Mounjaro describe the same arc: an unsettled first fortnight, then a settling. By week four, appetite has usually shifted noticeably — earlier fullness, less interest in snacking, food taking up less mental space than it did before. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, and the opening four weeks are almost always spent at the 2.5 mg starter dose, which is calibrated for tolerance rather than maximum effect. It is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen contains four weekly doses of 2.5 mg. Many people feel little on day one. By days three to five, the medicine's effects on gastric emptying begin to register: food moves through the stomach more slowly, and fullness arrives sooner. For some people that shift is subtle; for others it is quite pronounced.
Nausea is the side effect reported most often in week one. It rarely arrives with any warning and can feel worse in the hour after eating a rich or fatty meal. Keeping portions moderate, eating slowly and staying well hydrated all help. The foods that sit most comfortably on Mounjaro tend to be plain, lower-fat options, something many people work out through trial and error in these early days.
Injection-site reactions (mild redness, itching) can occur. Rotating between the abdomen, thigh and upper arm, and allowing the pen to reach room temperature before use, reduces them. Your Patient Information Leaflet covers every detail of correct injection technique; follow it alongside any guidance from your prescriber.
This is typically when people notice the change most clearly. Portion sizes that felt normal a fortnight ago now feel too large. The urge to eat between meals quietens. Some people describe a reduced interest in foods they previously found hard to resist.
Weight loss, if it appears, is often modest at this stage, not because the medicine is not working, but because 2.5 mg is the settling-in dose. The SURMOUNT-1 trial, published in the New England Journal of Medicine, measured its results over 72 weeks across thousands of participants; month one is the foundation of that longer journey. Comparing your four-week result to someone else's or to the trial's headline figures misses how the medicine is designed to work.
GI side effects often ease noticeably by week three, though they do not disappear entirely for everyone at this stage. Constipation replaces nausea as the more common complaint for some people; fibre, fluids and gentle movement help. If diarrhoea or vomiting is severe and persistent, contact your prescriber, serious dehydration can follow.
Week four is the natural pause point. Your first pen is complete and a prescriber reviews whether to continue at 2.5 mg or move to 5 mg. At nume, every repeat order receives a fresh clinical review before dispatch, a named prescriber reads your update, not automated software.
Most people do move to 5 mg at this point, but clinical review sometimes recommends staying at 2.5 mg if side effects are still noticeable. That is not a setback; it is the titration schedule working exactly as intended. The NHS tirzepatide page explains why gradual dose increases are built into the treatment plan.
If you are curious about what tends to happen next, month two on Mounjaro typically brings the first therapeutic dose and, for many people, more visible progress on the scales. Many people also find it useful to read about what the first month on Mounjaro is actually like to set realistic expectations before they begin.
On the cost side, understanding how Mounjaro is priced across UK providers is worth doing before you start, so that the ongoing expense does not come as a surprise. Current pricing at nume is shown on the treatment page, alongside everything that is included in the one transparent price.
Most people move through their first four weeks without anything that requires urgent attention. A few situations do warrant a call or message to your prescriber rather than waiting. Severe, persistent stomach pain that extends to your back (with or without vomiting) should be assessed promptly; the MHRA's Drug Safety Update guidance on GLP-1 medicines identifies acute pancreatitis as an infrequent but serious risk. Signs of an allergic reaction (swelling, difficulty breathing, widespread rash) need emergency care. Significant dehydration from ongoing vomiting or diarrhoea, sudden changes in vision, or thoughts of self-harm are all reasons to seek help without delay.
Anything less urgent (questions about missed doses, what to eat, whether a symptom is normal) belongs with your prescriber or the aftercare team. At nume, that support runs seven days a week. The FAQs page covers common first-month questions, and if you want a clearer picture of the results and side effects people typically report at the four-week mark, what Mounjaro is like after 1 month is a useful read before you contact the team. The contact page connects you directly with the team. If you have not yet started and want to discuss whether tirzepatide is suitable for you, speaking to our prescribers through a free consultation is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.